Au­ven Ther­a­peu­tics sells PhI­II dry eye dis­ease drug to Sun for $40M-plus

Au­ven Ther­a­peu­tics has sold world­wide rights to its Phase III dry eye dis­ease ther­a­py — dubbed Seciera —   to In­dia’s Sun Phar­ma for $40 mil­lion plus un­spec­i­fied mile­stones. The com­pa­ny will an­nounce lat­er to­day that it made the sale through a sub­sidiary.

Slat­ed for com­ple­tion in ear­ly 2017, Au­ven re­cruit­ed 747 pa­tients for the late-stage study.

“Seciera has the po­ten­tial to be a best-in-class prod­uct and the first treat­ment for dry eye dis­ease that ad­dress­es both tear pro­duc­tion and in­flam­ma­tion of the oc­u­lar sur­face” said Dr. Pe­ter B. Corr, man­ag­ing gen­er­al Part­ner of Au­ven Ther­a­peu­tics. “In ad­di­tion, Seciera of­fers key im­prove­ments in ear­li­er on­set of pos­i­tive ef­fects and lack of ap­pli­ca­tion dis­com­fort over cur­rent­ly avail­able ther­a­pies.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER